Streptokinase, a 47-kDa protein isolated and secreted by most group A, C and G ß-hemolytic streptococci, interacts with and activates human protein plasminogen to form an active complex capable of converting other plasminogen molecules to plasmin. Our objective was to compare five streptokinase formulations commercially available in Brazil in terms of their activity in the in vitro tests of euglobulin clot formation and of the hydrolysis of the plasmin-specific substrate S-2251(TM). Euglobulin lysis time was determined using a 96-well microtiter plate. Initially, human thrombin (10 IU/ml) and streptokinase were placed in individual wells, clot formation was initiated by the addition of plasma euglobulin, and turbidity was measured at 340 nm...
Myocardial infarction (MI) and ischemic stroke (IS) are caused by blood clots blocking arteries and ...
SUMMARY A simple screening method for determining the fibrinolytic activity of plasma is de-scribed....
Development of appropriate clinical dose regimens of individual plasminogen activators such as tissu...
Streptokinase, a 47-kDa protein isolated and secreted by most group A, C and G ß-hemolytic streptoco...
A novel and precise assay that facilitates high-throughput screening of fibrinolytic agents was deve...
See page 858 for the editorial comment on this article (doi:10.1093/eurheartj/ehi219) Aims The dosag...
Orientador : Jose Luiz DonatoDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade d...
Background: Streptokinase is a potent activator of plasminogen to plasmin, the enzyme that can solub...
AbstractPurpose: Presumed differences in the thrombolytic activity and fibrinolytic specificity of t...
In previous studies (1, 4), a method was developed for the quantitative recording of the lysis of th...
BACKGROUND: There is currently no universal and standardized test available to phenotype plasma fibr...
Abstract Background Thrombolytic drugs are widely used for the management of cerebral venous sinus t...
Despite the criticisms of substrate variability, the euglo-bulin lysis time remains a most useful as...
Arterial thrombosis is the underlying cause of a wide variety of cardiovascular diseases including m...
Streptokinase is an extracellular protein, extracted from certain strains of beta hemolytic streptoc...
Myocardial infarction (MI) and ischemic stroke (IS) are caused by blood clots blocking arteries and ...
SUMMARY A simple screening method for determining the fibrinolytic activity of plasma is de-scribed....
Development of appropriate clinical dose regimens of individual plasminogen activators such as tissu...
Streptokinase, a 47-kDa protein isolated and secreted by most group A, C and G ß-hemolytic streptoco...
A novel and precise assay that facilitates high-throughput screening of fibrinolytic agents was deve...
See page 858 for the editorial comment on this article (doi:10.1093/eurheartj/ehi219) Aims The dosag...
Orientador : Jose Luiz DonatoDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade d...
Background: Streptokinase is a potent activator of plasminogen to plasmin, the enzyme that can solub...
AbstractPurpose: Presumed differences in the thrombolytic activity and fibrinolytic specificity of t...
In previous studies (1, 4), a method was developed for the quantitative recording of the lysis of th...
BACKGROUND: There is currently no universal and standardized test available to phenotype plasma fibr...
Abstract Background Thrombolytic drugs are widely used for the management of cerebral venous sinus t...
Despite the criticisms of substrate variability, the euglo-bulin lysis time remains a most useful as...
Arterial thrombosis is the underlying cause of a wide variety of cardiovascular diseases including m...
Streptokinase is an extracellular protein, extracted from certain strains of beta hemolytic streptoc...
Myocardial infarction (MI) and ischemic stroke (IS) are caused by blood clots blocking arteries and ...
SUMMARY A simple screening method for determining the fibrinolytic activity of plasma is de-scribed....
Development of appropriate clinical dose regimens of individual plasminogen activators such as tissu...